RGEN

$176.946.20%-11.70

Repligen Corp (RGEN)

Date: O: H: L: C: Vol:

전일 마감가:

$188.64

열려 있는:

$177.44

하루 거래량:

4,472,065

상대 거래량:

2.98

시가총액:

$11.23B

수익:

$763.34M

순이익/손실:

$51.40M

주가수익비율:

194.78

EPS:

$0.9084

순현금흐름:

$104.46M

1W 성능:

-1.79%

1M 성능:

-2.62%

6M 성능:

+50.97%

1Y 성능:

+18.70%

1일 변동 폭

$0.00$0.00

1주일 범위

$164.88$191.05

52주 변동 폭

$100.99$198.87

Repligen Corp 주식 (RGEN) 회사 개요

명칭

Repligen Corp

부문

Healthcare

산업

Medical Instruments & Supplies

전화

(781) 449-9560

주소

41 SEYON STREET, WALTHAM, MA, USA

직원

2,000

@repligen

다음 수익 날짜

null

최신 SEC 제출 서류

SEC

X에서 RGEN에 대한 토론

RGEN vs ISRG, BDX, ALC, RMD, WST 비교

주식	시가총액	매출	순이익	현금흐름	주당 순 이익
RGEN Repligen Corp	$11.23B	$763.34M	$51.40M	$104.46M	$0.9084
ISRG Intuitive Surgical Inc	$152.62B	$11.03B	$3.16B	$3.22B	$8.73
BDX Becton Dickinson Co	$53.90B	$21.37B	$1.41B	$3.07B	$3.94
ALC Alcon Inc	$34.54B	$10.63B	$819.00M	$1.59B	$1.66
RMD Resmed Inc	$32.34B	$5.54B	$1.52B	$1.74B	$10.37
WST West Pharmaceutical Services Inc	$28.74B	$3.22B	$542.70M	$458.00M	$7.48

Repligen Corp 주식(RGEN) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-09-09	Resumed	UBS	Buy
2026-07-07	업그레이드	The Benchmark Company	Hold → Buy
2026-06-02	Resumed	Wolfe Research	Outperform
2026-05-15	Resumed	RBC Capital Mkts	Outperform
2026-04-17	개시	Rothschild & Co Redburn	Buy
2025-10-01	개시	HSBC Securities	Buy
2025-09-22	업그레이드	Evercore ISI	In-line → Outperform
2025-07-22	Resumed	Stephens	Overweight
2025-06-24	개시	Barclays	Overweight
2025-04-29	업그레이드	Wolfe Research	Peer Perform → Outperform
2025-03-18	개시	Evercore ISI	In-line
2025-02-10	개시	TD Cowen	Buy
2024-12-17	개시	Canaccord Genuity	Hold
2024-11-14	개시	Wolfe Research	Peer Perform
2024-08-28	개시	Wells Fargo	Overweight
2024-06-26	업그레이드	Deutsche Bank	Hold → Buy
2024-06-18	개시	Guggenheim	Neutral
2023-12-04	다운그레이드	The Benchmark Company	Buy → Hold
2023-07-20	개시	Wells Fargo	Overweight
2023-07-05	Resumed	JP Morgan	Overweight
2023-03-28	개시	The Benchmark Company	Buy
2022-12-14	개시	Deutsche Bank	Hold
2022-12-07	개시	RBC Capital Mkts	Sector Perform
2022-07-20	개시	UBS	Buy
2021-10-14	개시	Exane BNP Paribas	Outperform
2020-11-10	개시	KeyBanc Capital Markets	Overweight
2020-08-24	재확인	H.C. Wainwright	Buy
2020-06-30	재확인	H.C. Wainwright	Buy
2020-05-07	재확인	H.C. Wainwright	Buy
2020-03-23	재확인	H.C. Wainwright	Buy
2019-11-15	개시	Stifel	Buy
2019-11-01	업그레이드	First Analysis Sec	Outperform → Strong Buy
2019-10-15	개시	SVB Leerink	Outperform
2019-08-28	재확인	First Analysis Sec	Outperform
2019-08-23	Resumed	Stephens	Overweight
2019-07-22	업그레이드	H.C. Wainwright	Neutral → Buy
2018-12-17	업그레이드	CL King	Neutral → Buy
2018-11-12	다운그레이드	CL King	Buy → Neutral
2018-09-26	개시	H.C. Wainwright	Neutral
2017-12-08	개시	Citigroup	Buy
2017-12-05	개시	JP Morgan	Overweight
2017-11-13	개시	CL King	Buy
2017-10-02	업그레이드	First Analysis Sec	Equal-Weight → Overweight
2017-07-21	개시	William Blair	Outperform
2017-02-13	업그레이드	Piper Jaffray	Neutral → Overweight

Repligen Corp (RGEN) 재무 분석

기간	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
기간 종료일	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	738.26	634.44	632.36	801.54	670.53
Cost of revenue USD (M)	352.01	359.79	353.92	345.83	279.28
Gross profit USD (M)	-	-	284.84	455.71	391.25
Research and development USD (M)	54.18	43.20	42.72	43.94	34.27
Operating expenses USD (M)	683.09	669.55	230.27	231.04	224.01
Operating income USD (M)	55.17	-35.11	47.70	224.67	167.25
Income before tax USD (M)	62.38	-27.04	56.71	219.14	153.54
Income tax expense USD (M)	13.49	-1.52	21.11	33.18	25.25
Net income USD (M)	48.89	-25.51	35.60	185.96	128.29
Basic EPS USD/shares	0.87	-0.46	0.64	3.35	2.33
Diluted EPS USD/shares	0.86	-0.46	0.63	3.24	2.24
Basic weighted shares shares (M)	0.06	0.06	0.06	0.06	55.02
Diluted weighted shares shares (M)	0.06	0.06	0.06	0.06	57.26
Selling, general and administrative USD (M)	290.51	263.37	218.58	215.83	183.87

Repligen Corp 주식 (RGEN) 내부자 거래

Loeillot OlivierOct 05 '26
Officer
거래
Proposed Sale
비용
$190.00
#주식
4,202
가치 ($)
798,380
#주식 총계
0
Loeillot OlivierOct 05 '26
Chief Executive Officer
거래
Sale
비용
$187.29
#주식
5,535
가치 ($)
1,036,654
#주식 총계
45,788
Loeillot OlivierOct 05 '26
Officer
거래
Proposed Sale
비용
$178.75
#주식
1,333
가치 ($)
238,274
#주식 총계
0
Loeillot OlivierSep 24 '26
Chief Executive Officer
거래
Sale
비용
$190.00
#주식
12,946
가치 ($)
2,459,740
#주식 총계
48,369
Loeillot OlivierSep 24 '26
Chief Executive Officer
거래
Option Exercise
비용
$155.11
#주식
12,946
가치 ($)
2,008,020
#주식 총계
56,773
Loeillot OlivierSep 24 '26
Officer
거래
Proposed Sale
비용
$190.00
#주식
12,946
가치 ($)
2,459,740
#주식 총계
0
Loeillot OlivierSep 21 '26
Chief Executive Officer
거래
Sale
비용
$180.00
#주식
5,426
가치 ($)
976,680
#주식 총계
48,369
Loeillot OlivierSep 21 '26
Chief Executive Officer
거래
Option Exercise
비용
$141.79
#주식
5,426
가치 ($)
769,353
#주식 총계
53,795
Loeillot OlivierSep 21 '26
Officer
거래
Proposed Sale
비용
$180.00
#주식
5,426
가치 ($)
976,680
#주식 총계
0
Loeillot OlivierSep 04 '26
Chief Executive Officer
거래
Sale
비용
$165.90
#주식
3,035
가치 ($)
503,506
#주식 총계
48,369

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Loeillot Olivier	Officer	Oct 05 '26	Proposed Sale	$190.00	4,202	798,380	0
Loeillot Olivier	Chief Executive Officer	Oct 05 '26	Sale	$187.29	5,535	1,036,654	45,788
Loeillot Olivier	Officer	Oct 05 '26	Proposed Sale	$178.75	1,333	238,274	0
Loeillot Olivier	Chief Executive Officer	Sep 24 '26	Sale	$190.00	12,946	2,459,740	48,369
Loeillot Olivier	Chief Executive Officer	Sep 24 '26	Option Exercise	$155.11	12,946	2,008,020	56,773
Loeillot Olivier	Officer	Sep 24 '26	Proposed Sale	$190.00	12,946	2,459,740	0
Loeillot Olivier	Chief Executive Officer	Sep 21 '26	Sale	$180.00	5,426	976,680	48,369
Loeillot Olivier	Chief Executive Officer	Sep 21 '26	Option Exercise	$141.79	5,426	769,353	53,795
Loeillot Olivier	Officer	Sep 21 '26	Proposed Sale	$180.00	5,426	976,680	0
Loeillot Olivier	Chief Executive Officer	Sep 04 '26	Sale	$165.90	3,035	503,506	48,369

Repligen Corp 주식(RGEN)의 최신 뉴스

Oct 30, 2026

Form 8K Repligen Corporation For: 30 October By Investing.com - Investing.com UK

Oct 30, 2026

Oct 28, 2026

Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook - Yahoo Finance

Oct 28, 2026

Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings - Yahoo Finance

Oct 28, 2026

Canaccord reiterates Hold on Repligen stock after Q3 beat By Investing.com - Investing.com Canada

Oct 28, 2026

Oct 27, 2026

Repligen Posts Record Q3 Revenue, Narrows 2026 Organic Growth Outlook - TradingKey

Oct 27, 2026

Repligen (RGEN) Reports Record Q3 Revenue, Boosts 2026 Guidance Amid Acquisition - GuruFocus

Oct 27, 2026

Repligen Q3 2026 slides: record revenue, raised guidance, margins expand - Investing.com

Oct 27, 2026

Earnings call transcript: Repligen tops Q3 2026 forecasts but shares slip - Investing.com

Oct 27, 2026

Repligen Corp Reports Q3 2026 Results: $209.3 Million Revenue, G - GuruFocus

Oct 27, 2026

Repligen Q3 2026 Earnings Call Transcript - Benzinga

Oct 27, 2026

Repligen Q3 2026 Earnings Call Transcript - Benzinga

Oct 27, 2026

Q3 2026 Repligen Corporation Earnings Call Transcript - GuruFocus

Oct 27, 2026

Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations - Yahoo Finance

Oct 27, 2026

Form 8K Repligen Corporation For: 27 October By Investing.com - Investing.com Canada

Oct 27, 2026

Repligen Reports Q3 Revenue Growth, Raises 2026 Guidance - TradingView

Oct 27, 2026

Repligen earnings beat by $0.07, revenue topped estimates - Investing.com

Oct 27, 2026

Repligen: Q3 Earnings Snapshot - Yahoo Finance

Oct 27, 2026

Oct 26, 2026

symbol__ Stock Quote Price and Forecast - CNN

Oct 26, 2026

Repligen earnings in focus as bioprocessing growth accelerates - Investing.com

Oct 26, 2026

Oct 20, 2026

Repligen Corporation Bonds — Corporate Bond Rates - TradingView

Oct 20, 2026

Las ETF que invierten en acciones de Repligen Corporation - TradingView

Oct 20, 2026

Oct 17, 2026

Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance

Oct 17, 2026

Oct 15, 2026

Repligen Corp (RGEN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus

Oct 15, 2026

Oct 13, 2026

Repligen to Report Third Quarter 2026 Financial Results - Yahoo Finance

Oct 13, 2026

Oct 12, 2026

Form 144 REPLIGEN CORP For: 12 October By Investing.com - Investing.com Canada

Oct 12, 2026

RGEN5964422 Bond Profile: Coupon and Redemption - TradingView

Oct 12, 2026

Oct 10, 2026

Repligen Corp (BSP:R2GE34) Stock Holders - Institutional & Insider Ownership - GuruFocus

Oct 10, 2026

Oct 09, 2026

Is It Too Late to Buy Repligen Corp (RGEN) After 6.1% Rally? GF Value Says Undervalued - GuruFocus

Oct 09, 2026

Repligen Corp (RGEN) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus

Oct 09, 2026

Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance

Oct 09, 2026

Oct 08, 2026

A 700-share stock grant joins options with a $174.86 exercise price for Repligen (RGEN)’s chief product officer. - Stock Titan

Oct 08, 2026

Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus

Oct 08, 2026

Oct 07, 2026

One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. - Stock Titan

Oct 07, 2026

Repligen CEO Olivier Loeillot sells $1.03m of company stock By Investing.com - Investing.com Nigeria

Oct 07, 2026

Oct 06, 2026

Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,535 Shares - GuruFocus

Oct 06, 2026

Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tel - GuruFocus

Oct 06, 2026

Repligen CEO Olivier Loeillot sells $1.03m of company stock - Investing.com

Oct 06, 2026

Repligen (RGEN) CEO sells shares at $190 and $178.75 under a preset trading plan. - Stock Titan

Oct 06, 2026

Repligen Closes BioLife Solutions Acquisition - Yahoo Finance

Oct 06, 2026

Repligen completes acquisition of BioLife Solutions - Investing.com

Oct 06, 2026

18 commercially approved therapies are supported by BioLife's cell-preserving media. Repligen completed the deal. - stocktitan.net

Oct 06, 2026

Repligen Completes Acquisition of BioLife Solutions - Yahoo Finance

Oct 06, 2026

Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing - Yahoo Finance

Oct 06, 2026

Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com South Africa

Oct 06, 2026

Oct 05, 2026

Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus

Oct 05, 2026

Loeillot proposes selling 4,202 Repligen (RGEN) shares through Fidelity. - stocktitan.net

Oct 05, 2026

RGEN와(과) 유사한 종목

Repligen Corp (RGEN)

Repligen Corp 주식 (RGEN) 회사 개요

RGEN vs ISRG, BDX, ALC, RMD, WST 비교

Repligen Corp 주식(RGEN) 업그레이드 및 다운그레이드

Repligen Corp (RGEN) 재무 분석

Repligen Corp 주식 (RGEN) 내부자 거래

Repligen Corp 주식(RGEN)의 최신 뉴스

Form 8K Repligen Corporation For: 30 October By Investing.com - Investing.com UK

Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook - Yahoo Finance

Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings - Yahoo Finance

Canaccord reiterates Hold on Repligen stock after Q3 beat By Investing.com - Investing.com Canada

Repligen Posts Record Q3 Revenue, Narrows 2026 Organic Growth Outlook - TradingKey

Repligen (RGEN) Reports Record Q3 Revenue, Boosts 2026 Guidance Amid Acquisition - GuruFocus

Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Re - GuruFocus

Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Re - GuruFocus

Repligen Corporation Q3 2026 Earnings Call Summary - Yahoo Finance

Conestoga Small Cap Composite Q3 2026 Portfolio Activity - Seeking Alpha

Repligen Q3 2026 slides: record revenue, raised guidance, margins expand - Investing.com

Earnings call transcript: Repligen tops Q3 2026 forecasts but shares slip - Investing.com

Repligen Corp Reports Q3 2026 Results: $209.3 Million Revenue, G - GuruFocus

Repligen Q3 2026 Earnings Call Transcript - Benzinga

Repligen Q3 2026 Earnings Call Transcript - Benzinga

Q3 2026 Repligen Corporation Earnings Call Transcript - GuruFocus

Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations - Yahoo Finance

Form 8K Repligen Corporation For: 27 October By Investing.com - Investing.com Canada

Repligen Reports Q3 Revenue Growth, Raises 2026 Guidance - TradingView

Repligen earnings beat by $0.07, revenue topped estimates - Investing.com

Repligen: Q3 Earnings Snapshot - Yahoo Finance

symbol__ Stock Quote Price and Forecast - CNN

Repligen earnings in focus as bioprocessing growth accelerates - Investing.com

Repligen Corporation Bonds — Corporate Bond Rates - TradingView

Las ETF que invierten en acciones de Repligen Corporation - TradingView

Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance

Repligen Corp (RGEN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus

Repligen to Report Third Quarter 2026 Financial Results - Yahoo Finance

Form 144 REPLIGEN CORP For: 12 October By Investing.com - Investing.com Canada

RGEN5964422 Bond Profile: Coupon and Redemption - TradingView

Repligen Corp (BSP:R2GE34) Stock Holders - Institutional & Insider Ownership - GuruFocus

Is It Too Late to Buy Repligen Corp (RGEN) After 6.1% Rally? GF Value Says Undervalued - GuruFocus

Repligen Corp (RGEN) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus

Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance

A 700-share stock grant joins options with a $174.86 exercise price for Repligen (RGEN)’s chief product officer. - Stock Titan

Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus

One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. - Stock Titan

Repligen CEO Olivier Loeillot sells $1.03m of company stock By Investing.com - Investing.com Nigeria

Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,535 Shares - GuruFocus

Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tel - GuruFocus

Repligen CEO Olivier Loeillot sells $1.03m of company stock - Investing.com

Repligen (RGEN) CEO sells shares at $190 and $178.75 under a preset trading plan. - Stock Titan

Repligen Closes BioLife Solutions Acquisition - Yahoo Finance

Repligen completes acquisition of BioLife Solutions - Investing.com

18 commercially approved therapies are supported by BioLife's cell-preserving media. Repligen completed the deal. - stocktitan.net

Repligen Completes Acquisition of BioLife Solutions - Yahoo Finance

Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing - Yahoo Finance

Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com South Africa

Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus

Loeillot proposes selling 4,202 Repligen (RGEN) shares through Fidelity. - stocktitan.net

RGEN와(과) 유사한 종목